217 related articles for article (PubMed ID: 29989571)
21. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
22. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
23. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
24. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.
Matveeva OV; Chumakov PM
Rev Med Virol; 2018 Nov; 28(6):e2008. PubMed ID: 30209859
[TBL] [Abstract][Full Text] [Related]
25. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
[TBL] [Abstract][Full Text] [Related]
27. Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy.
Matveeva OV; Shabalina SA
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291506
[TBL] [Abstract][Full Text] [Related]
28. Potential and clinical translation of oncolytic measles viruses.
Robinson S; Galanis E
Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716
[TBL] [Abstract][Full Text] [Related]
29. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
30. Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.
Angarita FA; Acuna SA; Ottolino-Perry K; Zerhouni S; McCart JA
Trends Mol Med; 2013 Jun; 19(6):378-92. PubMed ID: 23540715
[TBL] [Abstract][Full Text] [Related]
31. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
Park GT; Choi KC
Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
[TBL] [Abstract][Full Text] [Related]
32. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
34. [Current state of oncolytic virotherapy in Japan].
Nakamori M; Yamaue H
Gan To Kagaku Ryoho; 2013 May; 40(5):553-8. PubMed ID: 23863576
[TBL] [Abstract][Full Text] [Related]
35. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
36. Viral oncolysis - can insights from measles be transferred to canine distemper virus?
Lapp S; Pfankuche VM; Baumgärtner W; Puff C
Viruses; 2014 Jun; 6(6):2340-75. PubMed ID: 24921409
[TBL] [Abstract][Full Text] [Related]
37. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
38. [Oncolytic viruses for therapy of malignant glioma].
Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
[TBL] [Abstract][Full Text] [Related]
39. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
40. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
Kim J; Hall RR; Lesniak MS; Ahmed AU
Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
